Black Diamond Therapeutics Inc. (BDTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
BDTX Stock Price Chart Interactive Chart >
BDTX Price/Volume Stats
| Current price | $3.00 | 52-week high | $4.62 |
| Prev. close | $3.01 | 52-week low | $1.18 |
| Day low | $2.99 | Volume | 58,884 |
| Day high | $3.14 | Avg. volume | 190,945 |
| 50-day MA | $2.09 | Dividend yield | N/A |
| 200-day MA | $2.39 | Market Cap | 109.10M |
Black Diamond Therapeutics Inc. (BDTX) Company Bio
Black Diamond Therapeutics, Inc. engages in the biotechnology company that discovers and develops therapeutic agents to target unique oncogenic protein-isoforms. The company was founded by Dr. David M. Epstein and Dr. Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.
Latest BDTX News From Around the Web
Below are the latest news stories about BLACK DIAMOND THERAPEUTICS INC that investors may wish to consider to help them evaluate BDTX as an investment opportunity.
private equity firms who own 40% along with institutions invested in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) saw increase in their holdings value last weekA look at the shareholders of Black Diamond Therapeutics, Inc. ( NASDAQ:BDTX ) can tell us which group is most... |
Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceCAMBRIDGE, Mass. and NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic driver mutations in patients with genetically defined cancers, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the 41 st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 9:00 a.m. PT in San Francisco, California. |
Black Diamond Therapeutics Announces Changes to Board of DirectorsCAMBRIDGE, Mass. and NEW YORK, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that Chairman of the Board of Directors, Robert (Bob) A. Ingram, has stepped down due to personal reasons. Existing Board member, Mark Velleca, M.D., Ph.D., has been appointed to succeed Mr. Ingram as the next Chairman. “Bob’s counsel, expertise and partnership have |
Black Diamond rises 8% on spinout of Launchpad Therapeutics (NASDAQ:BDTX)Black Diamond Therapeutics (BDTX) is trading ~8% higher premarket after the company said it had formed Launchpad Therapeutics, an antibody-focused precision oncology firm, with a… |
Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company- $30M Series A investment from Versant Ventures and NEA- CAMBRIDGE, Mass. and NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the formation of Launchpad Therapeutics, Inc. (Launchpad), an antibody-focused precision oncology company, together with a $30 million Series A investment by founding investors, Versant Ventures and New Enterp |
BDTX Price Returns
| 1-mo | 66.67% |
| 3-mo | 31.58% |
| 6-mo | -14.29% |
| 1-year | -28.06% |
| 3-year | -92.00% |
| 5-year | N/A |
| YTD | 66.67% |
| 2022 | -66.23% |
| 2021 | -83.37% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...